Comparison of 18F-FDG PET/CT and 18F-FAPI PET/CT in Systemic Staging of Newly Diagnosed Breast Cancer

被引:0
|
作者
Ji, Bin [1 ]
Li, Wenjia [2 ]
Wang, Wan [2 ]
Min, Kaiyin [1 ]
Yang, Bowen [1 ]
Wan, Qichang [3 ]
Liu, Junzhi [1 ]
Gao, Shi [1 ]
机构
[1] Jilin Univ, Dept Nucl Med, China Japan Union Hosp, Changchun 130033, Peoples R China
[2] Jilin Univ, Dept Breast Surg, China Japan Union Hosp, Changchun 130033, Peoples R China
[3] Guangzhou Med Univ, Affiliated Qingyuan Hosp, Qingyuan Peoples Hosp, Dept Nucl Med, Qingyuan 511500, Peoples R China
关键词
F-18-FAPI PET/CT; F-18-FDG PET/CT; Breast cancer; Systemic staging; Sensitivity;
D O I
10.1016/j.acra.2024.07.058
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives: The purpose of this study was to compare the performance of F-18-FAPI PET/CT and F-18-FDG PET/CT in systemic staging of newly diagnosed breast cancer. Methods: Breast cancer patients with initial clinical stage IIB-IIIC who have consequently underwent both F-18-FAPI and F-18-FDG PET/CT from June 2022 to June 2023 were retrospectively analyzed. New clinical stage was assigned to each patient if unsuspected level III axillary and extraaxillary regional lymph node metastases (URNM) and/or distant metastases were disclosed after PET/CT. Sensitivity for both tests was calculated on patient basis and lesion basis using histology or follow-up imaging as reference standard. Results: 38 patients were included. The overall upstaging rate was 47.4% for F-18-FAPI PET/CT (18/38) and 34.2% for F-18-FDG PET/CT (13/38). The rate of distant metastases disclosed by F-18-FAPI PET/CT was 5.5% in stage IIB patients, 30% in stage IIIA patients, 50% in stage IIIB patients, and 75% in stage IIIC patients. On patent-based analysis, the sensitivity of F-18-FAPI PET/CT was significantly different from that of F-18-FDG PET/CT in detecting URNM [100% (13/13) vs 53.8% (7/13), (P = 0.031)], but not for distant metastases [100% (10/10) vs 90% (9/10), (P = 1.000)]. On lesion-based analysis, the sensitivity of F-18-FAPI PET/CT was significantly higher than that of F-18-FDG PET/CT in detecting URNM [97.6% (41/42) vs 52.4% (22/42), (P < 0.001)] and distant metastases [98.1% (51/52) vs 67.3% (35/52), (P < 0.001)]. Conclusion: F-18-FAPI PET/CT leads to significant upstaging in newly diagnosed breast cancer, in a rate higher than F-18-FDG PET/CT. The significantly higher lesion-based sensitivity in unsuspected metastases implies a future role of F-18-FAPI PET/CT in evaluation of metastatic disease burden. (c) 2024 The Association of University Radiologists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:50 / 57
页数:8
相关论文
共 50 条
  • [21] 18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer
    Ulaner, Gary A.
    Castillo, Raychel
    Goldman, Debra A.
    Wills, Jonathan
    Riedl, Christopher C.
    Pinker-Domenig, Katja
    Jochelson, Maxine S.
    Gonen, Mithat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (11) : 1937 - 1944
  • [22] 18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer
    Gary A. Ulaner
    Raychel Castillo
    Debra A. Goldman
    Jonathan Wills
    Christopher C. Riedl
    Katja Pinker-Domenig
    Maxine S. Jochelson
    Mithat Gönen
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1937 - 1944
  • [23] Evaluation of 18F-FDG PET/MRI, 18F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer
    Sawicki, Lino M.
    Grueneisen, Johannes
    Schaarschmidt, Benedikt M.
    Buchbender, Christian
    Nagarajah, James
    Umutlu, Lale
    Antoch, Gerald
    Kinner, Sonja
    EUROPEAN JOURNAL OF RADIOLOGY, 2016, 85 (02) : 459 - 465
  • [24] Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma
    Cho, Shih-Feng
    Chang, Chin-Chuan
    Liu, Yi-Chang
    Chang, Chao-Sung
    Hsiao, Hui-Hua
    Liu, Ta-Chih
    Huang, Chiung-Tang
    Lin, Sheng-Fung
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2015, 31 (03): : 130 - 137
  • [25] Al18F-NOTA-FAPI PET/CT in the evaluation of gastric, liver, and pancreatic cancer and comparison with 18F-FDG PET/CT
    Xu, Weizhi
    Meng, Tinghua
    Pang, Yizhen
    Sun, Long
    Zhang, Jingjing
    Chen, Xiaoyuan
    Chen, Haojun
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [26] Comparison of 68Ga-FAPI versus 18F-FDG PET/CT for Initial Cancer Staging
    Taveira, Mateus
    RADIOLOGY-IMAGING CANCER, 2021, 3 (02):
  • [27] Comparison of 18F-FDG PET/CT and CT or MRI for the Preoperative Staging of Ovarian Cancer
    Jung, G.
    Lee, Y.
    Oh, S.
    Byun, J.
    Ryu, I
    Kim, S.
    Chung, S.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 188 (05)
  • [28] Comparison of 68Ga-FAPI-04 PET/CT with 18F-FDG PET/CT for diagnosis and staging of gastric and colorectal cancer
    Wang, Bin
    Zhao, Xinming
    Liu, Yunuan
    Zhang, Zhaoqi
    Chen, Xiaoshan
    Jing, Fenglian
    Chen, Xiaolin
    Hua, Yu
    Zhao, Jianqiang
    NUCLEAR MEDICINE COMMUNICATIONS, 2024, 45 (07) : 612 - 621
  • [29] Efficacy of 18F-FDG PET/CT for Breast Cancer
    Mittra, E.
    Quon, A.
    Gambhir, S. S.
    Iagaru, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S176 - S176
  • [30] The diagnostic value of 18F-FAPI-42 PET/CT for pulmonary artery masses: comparison with 18F-FDG PET/CT
    Hou, Peng
    Zhong, Kaixiang
    Guo, Wenliang
    Chen, Haiming
    Li, Youcai
    Ke, Miao
    Lv, Jie
    Liu, Shaoyu
    Zhong, Huizhen
    Fu Yimin
    Hong, Cheng
    Wang, Xinlu
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65